NeoGenomics/$NEO
1D1W1MYTD1Y5YMAX
Capital at risk
About NeoGenomics
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
- Ticker
- $NEO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- Fort Myers, United States
- Website
- www.neogenomics.com
NeoGenomics Metrics
BasicAdvanced
$2.3B
-
-$0.40
1.74
-
Price and volume
Market cap
$2.3B
Beta
1.74
52-week high
$19.76
52-week low
$7.07
Average daily volume
2.2M
Financial strength
Current ratio
3.603
Quick ratio
3.036
Long term debt to equity
56.373
Total debt to equity
57.064
Interest coverage (TTM)
-16.06%
Profitability
EBITDA (TTM)
24.325
Gross margin (TTM)
43.92%
Net profit margin (TTM)
-6.77%
Operating margin (TTM)
-5.41%
Effective tax rate (TTM)
4.89%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-1.89%
Return on equity (TTM)
-6.33%
Valuation
Price to revenue (TTM)
2.955
Price to book
2.86
Price to tangible book (TTM)
-235.83
Price to free cash flow (TTM)
-307.914
Free cash flow yield (TTM)
-0.32%
Free cash flow per share (TTM)
-0.057
Growth
Revenue change (TTM)
11.19%
Earnings per share change (TTM)
-51.01%
3-year revenue growth (CAGR)
11.58%
10-year revenue growth (CAGR)
15.90%
3-year earnings per share growth (CAGR)
-24.11%
10-year earnings per share growth (CAGR)
8.45%
What the Analysts think about NeoGenomics
Analyst ratings (Buy, Hold, Sell) for NeoGenomics stock.
Analyst projections of the future price of NeoGenomics stock.
NeoGenomics Financial Performance
Revenues and expenses
NeoGenomics Earnings Performance
Company profitability
Upcoming events
No upcoming events
NeoGenomics News
AllArticlesVideos
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire1 week ago
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
Business Wire2 weeks ago
Neo Performance Materials Q2 Earnings Call Highlights
MarketBeat4 weeks ago
Funds containing NeoGenomics
AllEURUSDGBP
Fund name | Fund size | $NEO weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.15% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.10% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.07% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.